Is Codexis Inc (CDXS) overvalued? · rev $59.3M
Codexis Inc (CDXS) is a biotechnology company listed on US.
This page asks whether Codexis Inc (CDXS) looks expensive on cached numbers — not a short thesis.
Latest reported CDXS revenue for 2024-12-31 was $59.3M. Net income was -$65.3M. Revenue was down 15.4% from 2023-12-31 to 2024-12-31. CDXS currently screens at market cap $257.6M.
CDXS currently screens at market cap $257.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CDXS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CDXS stock page for the full model, not this heading.
Not investment advice.